Drug Profile
Research programme: CD44-HCELL antibody - Inflazyme
Alternative Names: CD44-HCELL antibody research programme - InflazymeLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Inflazyme Pharmaceuticals
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bone marrow transplant rejection; Cancer; Immunodeficiency disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bone-marrow-transplant-rejection in Canada
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Canada
- 16 Jul 2016 No recent reports of development identified for preclinical development in Immunodeficiency-disorders in Canada